Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them.
Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.
Type | Public | |
Founded | 2007 | |
HQ | Cambridge, MA, US | Map |
Website | epizyme.com | |
Employee Ratings |
USD | |
---|---|
Revenue (Q1, 2021) | 7.6m |
Gross profit (Q1, 2021) | 4.8m |
Gross profit margin (Q1, 2021), % | 62.6% |
Net income (Q1, 2021) | (70.3m) |
EBIT (Q1, 2021) | (64.3m) |
Market capitalization (13-May-2022) | 54.1m |
Closing stock price (13-May-2022) | 0.5 |
Cash (31-Mar-2021) | 73.7m |
EV | 215.2m |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 12.0m | 7.9m | 5.9m | 5.7m | 1.4m | 2.5m | 3.6m | 7.6m | ||||||||||||||||
Cost of goods sold | 614.0k | 1.0m | 1.6m | 2.9m | ||||||||||||||||||||
Gross profit | 740.0k | 1.4m | 2.0m | 4.8m | ||||||||||||||||||||
Gross profit Margin, % | 55% | 59% | 55% | 63% |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 148.7m | 139.6m | 237.1m | 229.9m | 211.7m | 244.5m | 236.7m | 229.9m | 312.7m | 89.5m | 66.0m | 64.4m | 88.5m | 219.8m | 130.3m | 67.9m | 66.3m | 144.3m | 45.9m | 93.5m | 179.3m | 117.2m | 93.4m | 73.7m |
Accounts Receivable | 7.8m | 2.2m | 8.2m | 2.2m | 2.1m | 365.0k | 723.0k | 177.0k | 176.0k | 60.0k | 6.2m | 8.0k | 25.0k | 25.0k | 24.0k | 12.3m | 13.0m | 13.3m | 12.0m | 1.6m | 1.7m | 4.6m | 9.8m | |
Prepaid Expenses | 2.0m | 2.1m | 2.1m | 2.7m | 3.3m | 2.5m | 2.0m | 2.5m | 5.5m | 7.9m | 5.5m | 8.8m | 8.6m | 10.0m | 8.9m | 8.5m | 7.0m | 15.2m | 14.1m | 16.1m | 22.6m | 21.0m | 18.5m | 16.9m |
Inventories | 1.7m | 9.9m | 8.2m | 14.8m |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (9.7m) | (19.4m) | (6.9m) | (20.3m) | (40.0m) | (61.3m) | (87.1m) | (110.1m) | (22.9m) | (50.9m) | (75.2m) | (32.5m) | (60.5m) | (98.1m) | (34.1m) | (63.2m) | (100.7m) | (29.3m) | (77.8m) | (113.9m) | (50.9m) | (109.4m) | (165.5m) | (70.3m) |
Depreciation and Amortization | 363.0k | 534.0k | 169.0k | 362.0k | 548.0k | 260.0k | 653.0k | 1.1m | 389.0k | 791.0k | 1.2m | 411.0k | 824.0k | 1.2m | 361.0k | 582.0k | 804.0k | 207.0k | 416.0k | 626.0k | 512.0k | 1.4m | 2.7m | 1.3m |
Inventories | (1.7m) | (9.9m) | (8.2m) | (4.4m) | ||||||||||||||||||||
Accounts Payable | 290.0k | 364.0k | (1.3m) | (142.0k) | 1.1m | (3.2m) | (5.2m) | (5.3m) | (2.4m) | (980.0k) | (1.3m) | 1.9m | 4.6m | 366.0k | 226.0k | 4.0m | (701.0k) | 3.2m | 2.1m | 573.0k | (2.7m) | (4.2m) | (1.3m) | (4.8m) |
USD | Q2, 2013 |
---|---|
Financial Leverage | 1.7 x |
Epizyme has 2.9k Twitter Followers. The number of followers has decreased 0.1% month over month and decreased 0.3% quarter over quarter
628
Tweets
391
Following
2.9k
Followers
5
Tweets last 30 days
1.8
Avg. likes per Tweet
80%
Tweets with engagement
When was Epizyme founded?
Epizyme was founded in 2007.
Who are Epizyme key executives?
Epizyme's key executives are David M Mott, Grant Bogle and Matthew Ros.
How many employees does Epizyme have?
Epizyme has 203 employees.
What is Epizyme revenue?
Latest Epizyme annual revenue is $15.8 m.
What is Epizyme revenue per employee?
Latest Epizyme revenue per employee is $77.6 k.
Who are Epizyme competitors?
Competitors of Epizyme include Imago BioSciences, Italfarmaco and Ascentage Pharma.
Where is Epizyme headquarters?
Epizyme headquarters is located at 400 Technology Square, 400 Technology Square, Cambridge.
Where are Epizyme offices?
Epizyme has an office in Cambridge.
How many offices does Epizyme have?
Epizyme has 1 office.
Receive alerts for 300+ data fields across thousands of companies